Latest Disease-modifying antirheumatic drug Stories
MANILA, Philippines, April 6 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints.
KUALA LUMPUR, Malaysia, March 31 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints.
Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 30 percent of surveyed rheumatologists have altered their prescription patterns for juvenile idiopathic...
Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis.
ANN ARBOR, Mich. Jan. 7 /PRNewswire/ -- Velcura Therapeutics Inc., a clinical-phase biotechnology company developing therapies for bone disease, has completed its second successful Investigational New Drug application (IND) to the U.S.
NUTLEY, N.J., Dec. 4 /PRNewswire/ -- Roche today announced that the U.S.
ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc.
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment.
NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA).
Biogen Idec, a US-based pharmaceutical company, has announced that its Phase II trial of baminercept in rheumatoid arthritis patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug did not meet its primary endpoint.
- Withering but not falling off, as a blossom that persists on a twig after flowering.